News
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those with previous adverse reactions.
Could One of These Drugs Be the Next Ozempic? With dozens of drugs in development, semaglutide and tirzepatide may only be the beginning of next-generation diabetes and weight loss treatments.
People using weight loss medication have been warned it is not a "quick fix" with many at risk of regaining their lost weight ...
People using weight loss medication have been told it's not a "quick fix" with many at risk of regaining their lost weight.
The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...
Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.
The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.
4d
Clinical Trials Arena on MSNEli Lilly’s oral GLP-1RA hits endpoints, but trails Novo’s Wegovy in weight lossLilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.
10d
MedPage Today on MSNJustin Timberlake's Diagnosis; Senate Defies Trump on NIH; CMS' Wegovy Coverage PlanNote that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease. ( AP) Hulk Hogan's cause of death was acute myocardial infarction, ...
Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common ...
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results